These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 11927289

  • 1. Hsp90 inhibitors as novel cancer chemotherapeutic agents.
    Neckers L.
    Trends Mol Med; 2002; 8(4 Suppl):S55-61. PubMed ID: 11927289
    [Abstract] [Full Text] [Related]

  • 2. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
    Neckers L.
    Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
    [Abstract] [Full Text] [Related]

  • 3. Chaperoning oncogenes: Hsp90 as a target of geldanamycin.
    Neckers L.
    Handb Exp Pharmacol; 2006; (172):259-77. PubMed ID: 16610363
    [Abstract] [Full Text] [Related]

  • 4. Heat shock protein 90.
    Neckers L, Ivy SP.
    Curr Opin Oncol; 2003 Nov; 15(6):419-24. PubMed ID: 14624223
    [Abstract] [Full Text] [Related]

  • 5. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents.
    Neckers L, Neckers K.
    Expert Opin Emerg Drugs; 2002 Oct; 7(2):277-88. PubMed ID: 15989551
    [Abstract] [Full Text] [Related]

  • 6. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
    Neckers L.
    Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
    [Abstract] [Full Text] [Related]

  • 7. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y.
    Curr Pharm Des; 2005 May; 11(9):1131-8. PubMed ID: 15853661
    [Abstract] [Full Text] [Related]

  • 8. Heat shock protein 90 is a rational molecular target in breast cancer.
    Neckers L.
    Breast Dis; 2002 May; 15():53-60. PubMed ID: 15687645
    [Abstract] [Full Text] [Related]

  • 9. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.
    Blagosklonny MV.
    Leukemia; 2002 Apr; 16(4):455-62. PubMed ID: 11960322
    [Abstract] [Full Text] [Related]

  • 10. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
    Tsutsumi S, Neckers L.
    Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
    [Abstract] [Full Text] [Related]

  • 11. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
    Miyata Y.
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
    [Abstract] [Full Text] [Related]

  • 12. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.
    Ochel HJ, Eichhorn K, Gademann G.
    Cell Stress Chaperones; 2001 Apr; 6(2):105-12. PubMed ID: 11599571
    [No Abstract] [Full Text] [Related]

  • 13. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y, Ding J.
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [Abstract] [Full Text] [Related]

  • 14. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ, Margaritis LH, Voutsinas GE.
    Curr Med Chem; 2007 Aug; 14(29):3122-38. PubMed ID: 18220746
    [Abstract] [Full Text] [Related]

  • 15. Altered states: selectively drugging the Hsp90 cancer chaperone.
    Workman P.
    Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
    [Abstract] [Full Text] [Related]

  • 16. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ.
    Nature; 2003 Sep 25; 425(6956):407-10. PubMed ID: 14508491
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
    Koga F, Kihara K, Neckers L.
    Anticancer Res; 2009 Mar 25; 29(3):797-807. PubMed ID: 19414312
    [Abstract] [Full Text] [Related]

  • 18. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G, Caldas Lopes E, Solit D.
    Curr Opin Investig Drugs; 2006 Jun 25; 7(6):534-41. PubMed ID: 16784024
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic and diagnostic implications of Hsp90 activation.
    Kamal A, Boehm MF, Burrows FJ.
    Trends Mol Med; 2004 Jun 25; 10(6):283-90. PubMed ID: 15177193
    [Abstract] [Full Text] [Related]

  • 20. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV, Workman P.
    Endocr Relat Cancer; 2006 Dec 25; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.